The Federal Circuit reversed and remanded a Patent Trial and Appeal Board (the “Board”) decision declining to analyze patent claims as anticipated or obvious in an inter partes review (IPR) where the Board found the...more
2/14/2020
/ Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
Means-Plus-Function ,
Obviousness ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Remand ,
Reversal ,
Section 102 ,
Section 103 ,
Section 112
The Federal Circuit recently affirmed a district court’s determination, holding a group of patents invalid for indefiniteness.
In December 2014, HZNP Medicines LLC (“Horizon”) brought suit against Actavis Laboratories UT,...more
11/11/2019
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Generic Drugs ,
Indefiniteness ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
POSITA ,
Summary Judgment